Previous close | 0.7476 |
Open | 0.7500 |
Bid | 0.7171 x 100 |
Ask | 0.7748 x 100 |
Day's range | 0.7313 - 0.7500 |
52-week range | 0.7200 - 1.5600 |
Volume | |
Avg. volume | 232,112 |
Market cap | 28.596M |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6600 |
Earnings date | 05 Aug 2024 - 09 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.25 |
Key updates include leadership changes, significant workforce reduction, and promising developments in cancer treatment trials.
Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Dev
Just because a business does not make any money, does not mean that the stock will go down. For example, although...